Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options (NCT02650401)

🧪 Interventions in This Study

• Entrectinib (DRUG)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Disease status:
2. Phase 1 portion (closed): Participants must have measurable or evaluable disease, as defined by RECIST v1.1
3. Phase 2 portion:
4. Part B: Participants must have measurable or evaluable disease, as defined by RANO
5. Part C (closed): Participants must have measurable or evaluable disease, as defined by RECIST v1.1 ± Curie Scale
6. Part D: Participants must have measurable or evaluable disease, as defined by RECIST v1.1
7. Part E (closed): Participants must have measurable or evaluable disease, as defined by RECIST v1.1 ± Curie Scale or RANO
8. Tumor type:
9. Phase 1 portion: \* Part A: Relapsed or refractory extracranial solid tumors
10. Phase 2 portion
11. Part B: Primary brain tumors with NTRK1/2/3 or ROS1 gene fusions; gene fusions are defined as those predicted to translate into a fusion protein with a functional TRKA/B/C or ROS1 kinase domain, without a concomitant second oncodriver as determined by a nucleic acid-based diagnostic testing method
12. Part D: Extracranial solid tumors (including NB) with NTRK1/2/3 or ROS1 gene fusions; gene fusions are defined as those predicted to translate into a fusion protein with a functional TRKA/B/C or ROS1 kinase domain, without a concomitant second oncodriver as determined by a nucleic acid-based diagnostic testing method

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (26 Sites)

Showing the first 25 of 26 sites.

• University of California San Diego — La Jolla, California
• UCSF Benioff Children's Hospital — San Francisco, California
• Children's Hospital Colorado — Aurora, Colorado
• Egleston Children's Hospital at Emory University Atlanta — Atlanta, Georgia
• University of Chicago — Chicago, Illinois
• Johns Hopkins University — Baltimore, Maryland
• Dana Farber Cancer Institute — Boston, Massachusetts
• Washington University,St. Louis Children's Hospital — St Louis, Missouri
• Memorial Sloan Kettering Cancer Center — New York, New York
• Nationwide Children's Hospital — Columbus, Ohio
• Oregon Health & Science Uni — Portland, Oregon
• Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
• St. Jude Children'S Research Hospital — Memphis, Tennessee
• Texas Children's Cancer and Hematology Center — Houston, Texas
• Primary Children's Hospital — Salt Lake City, Utah
• The Hospital for Sick Children — Toronto, Ontario
• Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine — Shanghai, Shanghai Municipality
• Beijing Children's Hospital, Capital Medical University — Beijing,
• Centre Leon Berard — Lyon,
• Hôpital de la Timone, Oncologie Pédiatrique — Marseille,
• Universitaetsklinikum Heidelberg — Heidelberg, Baden-Wurttemberg
• Hong Kong Children's Hospital — Hong Kong,
• Fondazione IRCCS Istituto Nazionale dei Tumori — Milan, Lombardy
• Hospital Infantil Universitario Nino Jesus — Madrid,
• Royal Marsden Hospital (Sutton) — London,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Solid Tumors

• Phase II Biomarker Study of BND-22 in Combination With Cemiplimab in Solid Tumors — Houston, Texas
• Study of AUBE00 in Patients With Solid Tumors — Grand Rapids, Michigan
• JAB-2485 Activity in Adult Patients With Advanced Solid Tumors — Detroit, Michigan
• Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors — Basking Ridge, New Jersey
• Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours — Edmonton, Alberta
• DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors — Los Angeles, California

Explore by condition: All Solid Tumors clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.